Enhancing nicotine vaccine immunogenicity with liposomes.
about
Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and ImmunostimulatorsEvaluating the immunogenicity of an intranasal vaccine against nicotine in mice using the Adjuvant Finlay Proteoliposome (AFPL1)New directions in nicotine vaccine design and use.Vaccines against drugs of abuse: where are we now?Effect of currently approved carriers and adjuvants on the pre-clinical efficacy of a conjugate vaccine against oxycodone in mice and rats.Adjuvants for vaccines to drugs of abuse and addiction.Optimization of a methamphetamine conjugate vaccine for antibody production in miceInvestigating hapten clustering as a strategy to enhance vaccines against drugs of abuseConjugate Vaccine Immunotherapy for Substance Use Disorder.A simple physiologically based pharmacokinetic model evaluating the effect of anti-nicotine antibodies on nicotine disposition in the brains of rats and humans.Biologics to treat substance use disorders: Current status and new directionsMethamphetamine Vaccines: Improvement through Hapten Design.A nanoparticle-based nicotine vaccine and the influence of particle size on its immunogenicity and efficacy.Engineering of a hybrid nanoparticle-based nicotine nanovaccine as a next-generation immunotherapeutic strategy against nicotine addiction: A focus on hapten density.Rational incorporation of molecular adjuvants into a hybrid nanoparticle-based nicotine vaccine for immunotherapy against nicotine addiction.Enhancing Efficacy and Stability of an Antiheroin Vaccine: Examination of Antinociception, Opioid Binding Profile, and Lethality.
P2860
Q26765446-F619FBF5-7309-455A-A0DA-6FD0C6448209Q30392892-1B7E6CE8-8443-4F8D-B66E-17EE4FD712DFQ33719424-5CE08CD8-2A48-4436-B64C-75C81EBD9A54Q33776777-EAD1C050-8D8A-427C-923C-C6710E38A70EQ35163178-F9CB5D9A-9FE4-436B-BD74-8E14FFC50BBDQ35493923-6C7AB3CC-8625-4A43-947C-0D65CFCC08B6Q36854009-D8C01C37-B730-4601-A600-D85D4AC68F5FQ37697064-06DA0993-6A68-451E-8697-A8608F351224Q39387013-2166D3B1-5AEB-421A-BE7F-410C428FFB59Q39544975-BE3B1232-BF3E-47A7-925B-A3623FCF0F7CQ39576940-C9D8F34B-5A77-43E9-8487-A541371863B4Q42113438-518906D4-0D0F-4593-AD9D-4BE7AC9545D5Q45040238-61D15083-0C9A-4CE0-94F8-6AB3C3D7BC40Q45052268-FEDF0D53-D0C8-4B89-9276-CB457566A718Q45074067-CE35E336-87A6-4853-9C14-DD65AF000156Q50113262-BA4239C4-7375-423B-82D0-02592322C185
P2860
Enhancing nicotine vaccine immunogenicity with liposomes.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Enhancing nicotine vaccine immunogenicity with liposomes.
@ast
Enhancing nicotine vaccine immunogenicity with liposomes.
@en
type
label
Enhancing nicotine vaccine immunogenicity with liposomes.
@ast
Enhancing nicotine vaccine immunogenicity with liposomes.
@en
prefLabel
Enhancing nicotine vaccine immunogenicity with liposomes.
@ast
Enhancing nicotine vaccine immunogenicity with liposomes.
@en
P2093
P2860
P1476
Enhancing nicotine vaccine immunogenicity with liposomes.
@en
P2093
Gary Fujii
Jonathan W Lockner
Karen C McCague
Kim D Janda
Su Ming Chiang
P2860
P304
P356
10.1016/J.BMCL.2012.12.048
P407
P577
2012-12-27T00:00:00Z